title: Recombinant viruses as a tool for therapeutic vaccination against human cancers.
abstract: Viral vectors can be used to express a variety of genes in vivo, that encode tumor associated antigens, cytokines, or accessory molecules. For vaccination purposes, the ideal viral vector should be safe and enable efficient presentation of expressed antigens to the immune system. It should also exhibit low intrinsic immunogenicity to allow for its re-administration in order to boost relevant specific immune responses. Furthermore, the vector system must meet criteria that enable its industrialization. The characteristics of the most promising viral vectors, including retroviruses, poxviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, and alphaviruses, will be reviewed in this communication. Such recombinant viruses have been successfully used in animal models as therapeutic cancer vaccines. Based on these encouraging results, a series of clinical studies, reviewed herein, have been undertaken. Human clinical trials, have as of today, allowed investigators to establish that recombinant viruses can be safely used in cancer patients, and that such recombinants can break immune tolerance against tumor-associated antigens. These promising results are now leading to improved immunization protocols associating recombinant viruses with alternate antigen-presentation platforms (prime-boost regimens), in order to elicit broad tumor-specific immune responses (humoral and cellular) against multiple target antigens.
authors.affiliation: Aventis Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280, Marcy l'Etoile, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Bonnet
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: F
authors.initials: F
authors.lastname: Verdier
authors.forename: P
authors.initials: P
authors.lastname: Kourilsky
authors.forename: A
authors.initials: A
authors.lastname: Lindberg
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: P
authors.initials: P
authors.lastname: Moingeon
mesh_terms: D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000235:genetics* / Q000627:therapeutic use; D005822:Genetic Vectors / Q000009:adverse effects / Q000235:genetics* / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D016233:Immunotherapy, Active; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004279:DNA, Viral; D014614:Vaccines, Synthetic